| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test | Frank Vinluan | 04/21/20 | New York |
| Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More | Sarah de Crescenzo | 12/06/19 | National |
| Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More | Frank Vinluan | 05/31/19 | National |
| Nektar Forms New Company Inheris to Take Reins on Pain, CNS Drugs | Frank Vinluan | 05/23/19 | San Francisco |
| Oclaro Buys Mintera, Gazelle Gets $12M, Genzyme Buyout Rumors Swirl, & More Boston-Area Deals News | Erin Kutz | 07/28/10 | Boston |
| Taris Hires New CEO, Stromedix Hopes Clinical Trial Will Advance, Euthymics Hits the Ground With Series A, & More Boston-Area Life Sciences News | Erin Kutz | 07/23/10 | Boston |
| Cara Therapeutics Captures $15M | Ryan McBride | 07/21/10 | Boston |
| Cara Therapeutics Obtains $15,000,000 Series D Round | VentureDeal | 07/21/10 | Boston |
| New England’s Top Third-Quarter Venture Deals—the List | Robert Buderi | 10/20/08 | Boston |
| Cara Therapeutics Garners $12,300,000 Series C Round | VentureDeal | 07/25/08 | Boston |
